<code id='F251714F38'></code><style id='F251714F38'></style>
    • <acronym id='F251714F38'></acronym>
      <center id='F251714F38'><center id='F251714F38'><tfoot id='F251714F38'></tfoot></center><abbr id='F251714F38'><dir id='F251714F38'><tfoot id='F251714F38'></tfoot><noframes id='F251714F38'>

    • <optgroup id='F251714F38'><strike id='F251714F38'><sup id='F251714F38'></sup></strike><code id='F251714F38'></code></optgroup>
        1. <b id='F251714F38'><label id='F251714F38'><select id='F251714F38'><dt id='F251714F38'><span id='F251714F38'></span></dt></select></label></b><u id='F251714F38'></u>
          <i id='F251714F38'><strike id='F251714F38'><tt id='F251714F38'><pre id='F251714F38'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:728
          Perrigo Opill press photo – pharma coverage from STAT
          Opill, the first over-the-counter birth control pill, is on its way to U.S. stores. Perrigo via AP

          WASHINGTON — The first over-the-counter birth control pill will be available in U.S. stores later this month, allowing American women and teens to purchase contraceptive medication as easily as they buy aspirin.

          Manufacturer Perrigo said Monday it has begun shipping the medication, Opill, to major retailers and pharmacies. A one-month supply will cost about $20 and a three-month supply will cost around $50, according to the company’s suggested retail price. It will also be sold online.

          advertisement

          The launch has been closely watched since last July, when the Food and Drug Administration said the once-a-day Opill could be sold without a prescription. Ireland-based Perrigo noted there will be no age restrictions on sales, similar to other over-the-counter medications.

          Opill is an older class of contraceptive, sometimes called minipills, that contain a single synthetic hormone, progestin, and generally carry fewer side effects than more popular combination estrogen and progestin pills.

          Newsletters

          Sign up for Morning Rounds

          Understand how science, health policy, and medicine shape the world every day

          Please enter a valid email address. Privacy Policy

          The launch gives U.S. women another birth control option amid the legal and political battles over reproductive health, including the reversal of Roe v. Wade, which has upended abortion access across the U.S. Opill’s approval is unrelated to the ongoing court battles over the abortion pill mifepristone. And anti-abortion groups have generally emphasized that they do not oppose contraceptives to prevent pregnancies.

          advertisement

          Birth control pills are available without a prescription across much of South America, Asia, and Africa.

          The drug’s approval came despite some concerns by FDA scientists about the company’s results, including whether women with certain medical conditions would understand that they shouldn’t take the drug.

          Dr. Verda Hicks, president of the American College of Obstetricians and Gynecologists, in a statement, said studies have shown that patients, including adolescents, can effectively screen themselves to use the pills.

          — Matthew Perrone

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          The Harvard botanist who searched for psychedelics in the Amazon
          The Harvard botanist who searched for psychedelics in the Amazon

          RichardEvansSchultesintheCerroCampanamountainsinColombia,inJune1943.TheEstateofRichardEvansSchultes/

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

          OutgoingBristolCEOGiovanniCaforioEmiliePickeringforSTATIt’schangingoftheguardtimeatpharmaceuticalgia